Prevalence use of nonsteroidal anti-inflammatory drugs in the general population with COVID-19 and associated COVID-19 risk, hospitalization, severity, death, and safety outcomes: A systematic review and meta-analysis

Introduction: Recent reports of potential harmful effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with Corona Virus Disease 2019 (COVID-19) have provoked great concern. Therefore, the safety of NSAIDs is still questioned. Methods: We searched the PubMed, EMBASE, Cochrane Library and Web of Science databases from December 2019 to January 2021 to examine use prevalence for NSAIDs in general, as well as associated COVID-19 risk and outcomes. This study has been registered with PROSPERO (CRD42019132063) Results: We included 25 studies with a total of 101,215 COVID-19 patients. The use of NSAIDs in COVID-19 patients reached 19%. Exposure to NSAIDs was not associated with significantly increased risk of developing COVID-19 (odds ratio [OR]=0.98, 95% confidence interval [CI]: 0.78-1.24; I2=82%), hospitalization (OR=1.06, 95%CI: 0.76-1.48; I2=81%), mechanical ventilation (OR=0.71, 95%CI: 0.47-1.06; I2=38%), and length of hospital stay. Moreover, use of NSAIDs was significantly associated with better outcomes, including severity of COVID-19 (OR=0.79, 95%CI: 71-0.89; I2=0%) and death (OR=0.68, 95%CI: 0.52-0.89; I2=85%) in patients with COVID-19. Regarding safety outcomes, exposure to NSAIDs was associated with increased risk of stroke (OR=2.32, 95%CI: 1.04-5.2; I2=0%), but not with myocardial infraction (OR=1.49; p=0.66; I2=0%), overt thrombosis (OR=0.76, p=0.50; I2=28%) and major bleeding (p=0.61). Conclusion: Based on current evidence, exposure to NSAIDs is not linked to increased odds or exacerbation of COVID-19 in the general COVID-19 population. Furthermore, administration of NSAIDs might have better outcomes and survival benefits in the general COVID-19 population, although potentially increasing the risk of stroke. Use of NSAIDs might be safe and beneficial in COVID-19. Future observational and randomized control trials are needed for further confirmation.

Conclusion: Based on current evidence, exposure to NSAIDs is not linked to increased odds or exacerbation of COVID-19 in the general COVID-19 population.
Furthermore, administration of NSAIDs might have better outcomes and survival benefits in the general COVID-19 population, although potentially increasing the risk of stroke. Use of NSAIDs might be safe and beneficial in COVID-19. Future observational and randomized control trials are needed for further confirmation.
Keywords: nonsteroidal anti-inflammatory drugs, COVID-19, ibuprofen, aspirin, systematic review, meta-analysis . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

INTRODUCTION
Corona Virus Disease 2019  is an acute respiratory disease caused by the novel virus called severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2), which infects cells expressing the angiotensin-converting enzyme (ACE2) receptor and is currently prevalent worldwide [1,2].
Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, celecoxib, and indomethacin are inexpensive and readily available drugs widely applied for their antiviral and anti-inflammatory characteristics [3]. Moreover, since most clinical symptoms of COVID-19 usually start from fever, a sign of pain, NSAIDs might be the most commonly used drugs in the general population.
Therefore, NSAIDs provoke safety concerns in COVID-19. The concern was initially raised by several cases of COVID-19 reported by French researchers, with worsened symptoms after taking the NSAID ibuprofen [4]. Quite a few reports have revealed various side effects of NSAIDs and opposed their administration in . Subsequently, the European Medicines Agency and the WHO claimed NSAIDs should not be precluded when clinically indicated, at least not all of NSAIDs, based on limited evidence in the covid-19 epidemic.
NSAIDs exert their effects by suppressing cyclooxygenase enzymes so that the synthesis of prostaglandins (PGs) is reduced. Substances like prostaglandins are closely related to signs of pain, fever, and inflammation in patients with . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.01.21256428 doi: medRxiv preprint 6 6 COVID-19 [7]. Out of theoretical assumptions, studies suggested that exposure to NSAIDs might increase the risk of COVID-19; moreover, it is speculated that use of NSAIDs in COVID-19 patients may worsen the disease and increase the odds of ICU admission and death [8][9][10][11]. By contrast, other articles reported that prior exposure to NSAID does not significantly increase the risk of COVID-19 in general and is even associated with better outcomes (e.g., admission and death) in hospitalized e.g.,. In light of the ibuprofen-COVID-19 debate and the rapidly unfolding situation of the current pandemic, this study aimed to 1) assess the prevalence use of NSAIDs in the general COVID-19 population, 2) systematically investigate the associations of NSAID use with the risk of developing COVID-19 and related outcomes, and 3) assess the safety (particularly vascular complications) of NSAIDs in patients with COVID-19.

METHODS
This study was performed in accordance with PRISMA 2020 guidelines [15] (Table   S1 in Supplemental Materials) and has been registered on PROSPERO (International prospective register of systematic reviews) (registration number-CRD42019132063).

Literature search
Two independent researchers (Liu Xiao and Shanshan Huang) searched the PubMed, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) relevant studies without any language restrictions. We performed the search using the following keywords: "Nonsteroidal anti-inflammatory drug" OR "NSAID" AND "2019-novel coronavirus" OR "SARS-CoV-2" OR "COVID-19" OR "2019-nCoV".
Besides, references of related studies were also reviewed to discover more potentially relevant studies. Discrepancy was discussed by two researchers through online meeting until census were reached.

Study selection/inclusion and exclusion criteria
All included studies should meet the following criteria:1) recorded the use of NSAIDs prior or during the COVID-19 panic of general population. 2) evaluated the association between the use of NSAID and risk of developing COVID-19 and associated outcomes, such as hospitalization, severity and death in COVID-19 patients. Exclusion criteria were: 1) Reports focused on specific population, such as orthopedic and rheumatologic diseases were excluded. 2) Case reports, letters, reviews and expert opinions.

Data extraction and quality assessment
Two investigators (Xiao Liu and Shanshan Huang) independently extracted following information: name of first author's name, publication year, country, study design, sample size, mean or median age, sex, measure of exposure to NASIDs. Methods of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.01.21256428 doi: medRxiv preprint 8 8 astern COVID-19. In present study, the intensive care unit (ICU) admission was also considered as severe COVID-19 event. The quality and risk of bias of included studies reporting use of NSAIDs and associated outcomes (e.g., risk of COVID-19, severe COVID-19, and death) was assessed by the Joanna Briggs Institute (JBI) critical appraisal check-list and Newcastle-Ottawa quality scale (NOS), respectively [16,17]. [18]We regarded studies with an NOS of ≥ 6 stars as medium to high-quality studies; otherwise, are considered low-quality.

Outcomes
We firstly assessed the incidence of use of NASIDs in COVID-19 patients. Then the association between NASIDs and the risk of developing COVID-19 infection and associated outcomes (e.g., mechanical ventilation, hospitalization, severe COVID-19 infection, and mortality) was assessed. Finally, we focused on the safety of NASIDs use in COVID-19, particular vascular complications, such as bleeding, myocardial infraction, and stroke.

Statistical analysis
Meta-analysis was performed using international STATA15.0 (StataCorp, College Station, Texas) and RevMan5.3 (Review Manager [RevMan], version5.3, Cochrane Collaboration) software. The OR and 95% confidence intervals (95%CIs) were taken to evaluate the merged results. Risk ratio and hazard ratio from other studies were . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.01.21256428 doi: medRxiv preprint 9 9 regarded as OR. If not available, ORs could be obtained through calculating events and total numbers of patients in two groups. If both unadjusted and adjusted RRs existed in one study, we extracted both and pooled the unadjusted and adjusted, respectively. If multi-adjusted ORs were reported, we used the most completely adjusted one. The calculation and aggregation of natural logarithm of the OR (log [OR]) and its standard error (SElog [OR]) were conducted by Revman 5.3. As for evaluation of heterogeneity, Cochran's chi-square test and I 2 statistic was used. The random effects model were used to pooled the results. We also performed a subgroup analysis of types of NSAIDs which based on studies adjusted for confounding. The evaluation of publication bias was conducted by Egger's test and Begg's funnel plot. p < 0.05 represent there is statistical significance. Sensitivity analysis was conducted by omitting one study each.

Study selection
After searching the PubMed, Cochrane Library, EMBASE, and MedRxiv databases, we obtained 573 potentially relevant articles. Of these, 63 were duplicates. In addition, 447 studies were excluded after examining their titles and abstracts. Of the remaining 53 articles, 28 were excluded after a detailed review of the full text for the following reasons：1) 8 reports assessed other respiratory infections; 2) 7 were letters, reviews, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021.  [11][12][13] were included in the present analysis (Figure 1).

Study characteristics and quality
The basic characteristics of the included studies are shown in combined clinical and SARS-COV-2 PCR findings. The majority of studies were retrospective or prospective cohort observational trials; besides, 3 trials [22,24,29] were case-control studies. The assessment results showed that all articles were of medium to high quality (Table S2-3 in Supplemental Materials).

The impact of NSAID use on length of hospitalization in patients with COVID-19
There were 3 publications that reported the hospitalization length based on NSAID use (Table 2). We did not pool the results due to sufficient data. Jeong et al. [51] reported a median length of hospitalization of 12 days among NSAID users versus 13 days among non-users in COVID-19 patients. Another retrospective cohort including 412 American COVID-19 patients reported that there was no significant difference in the length of hospital stay between aspirin use and no-aspirin use [12]. A prospective cohort study that included 503 patients in Asia also showed that acute or chronic use of NSAID did not increase the length of hospital stay compared to non-NSAID users[11] (p=0.63). Collectively, current evidence showed NSAIDs did not increase the length of hospitalization in patients with COVID-19.

The impact of NSAID use on mechanical ventilation in patients with COVID-19
There were 6 studies [11,12,21,27,28,36]  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. OR=0.36, 95%CI: 0.03-3.96) ( Figure S3 in Supplemental Materials).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021.

Safety of NSAID use in patients with COVID-19
The cardiovascular adverse effects of NSAIDs, such as major bleeding, heart failure,  (Figure 6b-c). Moreover, Chow et al. [12] found no significant difference (6.1% aspirin vs. 7.6% non-aspirin, p=0.61) in major bleeding between groups in the crude analysis.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Publication bias and sensitive analysis
No publication bias for susceptibility to COVID-19 was detected by the funnel plot or the Egger's test (p>0.1), although these tests are not recommended for outcomes for which few studies are included (N<10) ( Figure S6 in Supplemental Materials).

DISCUSSION
At present, no consensual guidelines are available regarding NSAIDs use in COVID-19, reflecting a paucity of data in this regard. To the best of our knowledge, this study is the first meta-analysis that comprehensively assessed the incidence of NSAID use and associated outcomes in the general COVID-19 population. Our results showed a prevalence of NSAID use reaching 17% among the general population with COVID-19, which suggested the use of NSAIDs in patients with COVID-19 is not uncommon. Furthermore, based on current evidence, we found exposure to NSAIDs, including aspirin, ibuprofen and naproxen, was not associated with increased risk of developing COVID-19 or worse outcomes in patients with COVID-19. Notably, a significantly increased risk of thrombotic stroke was found in patients with COVID-19 administered NSAIDs (OR=2.32, p<0.04).
There is sound evidence that SARS-CoV-2 spike glycoprotein directly binds to the host cell's ACE2 receptor, which is highly expressed in human lung tissue, gastrointestinal tract, and arterial smooth muscle cells in vivo [54]. Indeed, the ACE receptor in humans . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. plays an important role in the pathophysiology of SARS-CoV-2 infection [55,56].
Several drugs with the potential of increasing ACE2 expression have provoked great concern for potentially contributing to the spread of COVID-19 in the population, Our results might be generalizable to a diverse population. In accordance with the above findings, several cohort studies also found no outcome worsening in . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.01.21256428 doi: medRxiv preprint Consistently, we also found a significantly increased risk of stroke, but no overt thrombosis or myocardial infarction rate elevation after NSAID use in hospitalized COVID-19 patients by pooling two propensity score-matched studies. The somewhat contradictory results were interesting. A possible explanation between thrombosis and clinical findings is the examination of overt thrombosis and microthrombosis, which is usually the cause of thrombosis stroke. It is well-known that the presence of microthrombi does not correlate with overt thrombosis. Microthrombosis is better diagnosed with video-microscopes, dark-field images, and spectral images. Therefore, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. NSAIDs would be helpful in providing sounder evidence on safety outcomes.
Age is an important confounding factor that might influence our results. Elderly people with comorbidities are more prone to routinely take NSAIDs[76] Although most of our data were adjusted for age, we cannot fully exclude the potential age-related bias. However, the NSAID groups were older in most of the included studies, and age-related adverse events cannot be underestimated. Furthermore, Wong et al. [40] reported that there is no association between NSAID use and COVID-19 related-death both in young and older individuals, and the estimated effect did not differ by age in all adjustment models. In general, current evidence suggested there is no interaction between age and NSAIDs in COVID-19.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021.

Study strengths and limitations
The greatest strength of this study was its large sample size, and all trials were general population-based. We examined the use rate of NSAIDs in COVID-19 cases and comprehensively assessed the related outcomes, including the risk of COVID-19, hospital admission, severity, mechanical ventilation and death, as well as safety outcomes. As readily available and inexpensive drugs, these results revealed benefits for the clinical use of NSAIDs during the COVID-19 pandemic.
We recognize possible limitations as well. 1) There are intrinsic limitations associated with any observational study, which is unable to prove a causal relationship.
2) The included individuals were adult, and the effects of NSAIDs in young individuals and children should be further studied. 3) Measured and unmeasured factors, such as various underlying diseases, may have influenced the above results. For example, it is . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. thought that there is a great gender difference in COVID-19. However, the limited data prevented sex-specific subgroup analysis. 4) Some data, including age and specific drug doses, were incomplete in most included studies and could not be further analyzed. However, Wong et al. [40] reported that high or low ibuprofen or naproxen is not linked to increased risk of COVID-19 death in the general population, which suggests NSAID use is safe at common clinical doses. 5) Significant heterogeneity was observed across the included studies, which might result from between-study differences, including differences in exposure to NSAIDs, types of NSAIDs and analytical strategies. Finally, well-randomized controlled clinical trials are still required for further assessment of the clinical benefit or harm of NSAIDs at proper doses in the prevention and treatment of COVID-19, while also trying to avoid their known side effects.

Conclusions
The current findings support the notion that exposure to NSAIDs is not linked to an elevated likelihood of susceptibility to or exacerbation of COVID-19; in addition, administration of NSAIDs might be beneficial to COVID-19 outcomes to some extent.
Thus, proper use of NSAIDs in COVID-19 is recommended, rather than absolute rejection. It is worth pointing out that this analysis was mostly based on observational studies, and ongoing trials (NCT0432563339, NCT0438276840, NCT0433462941 and NCT04344457) are expected to demonstrate the role of NSAIDs in the management of COVID-19. What's more, future investigations should not only focus . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. on the use of NSAIDs as a therapeutic option but also continue to examine the effects of pre-admission NSAID use on the risk of COVID-19 as well as  outcomes and mortality in the general population.

Ethics approval and consent to participate
Not applicable

Competing interests
All authors declare that they have no conflicts of interest.

Funding
This work was supported in part by the National Natural Science Foundation of China Postdoctoral Program for Innovative Talents (W.G-Z, BX20200400). Guangdong Medical Science and Technology Research Foundation (Y-J, A2021006);

Competing interests
All authors declare that they have no conflicts of interest.

Availability of supporting data
All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Consent for publication
Not applicable       C: Over thrombosis . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.01.21256428 doi: medRxiv preprint 2 6 2 6 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 5, 2021.